Abstract No : Abstract #LBA41
Indication : Gastric Cancer, Colorectal Cancer, Biliary tract cancer, Glioblastoma, Ovarian Cancer, Breast cancer
Intervention : Lenvatinib
Company : Merck & Co.
Technology : multiTKI
Results:
187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable
Conclusion:
187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable